Ike Jime or Bust: You've never seen anything like it. But, says Hauck, "There wasn't very many fish. Not that there isn't a market for sushi in Houston.
We spent a considerable amount of time with Michael, as well as the scientific founder team, understanding the nascent field of cancer metabolism and the early areas of interest: We got excited by the CMT concept, and things began heating up around the deal in early autumn.
Third Rock Ventures TRV had formed as a hot new venture firm in town that year, and we were working with them on our early obesity startup Zafgenwhere Kevin Starr had been on the board.
So working with them on CMT was easy. Other programs included autophagy inhibitors hydroxychloroquine and fatty acid enzymes CPT1C. While interesting, these early stage programs were risky on many dimensions e. We prepared a Series A proposal for CMT that involved a tranched financing, with a seed-stage derisking tranche, and a modest valuation.
We shared this concept with CMT in early November. Unfortunately for us, a competing proposal from Flagship and Arch won over the founders, and those two firms seeded the young startup shortly thereafter. So we put our pencils down.
In the weeks that followed, and continuing into the winter, a lengthy discussion was had about whether a 4-handed deal would make sense.
In the end, we could should have raised our hands, but we balked. Beyond the math problem posed by larger numbers of investors i. In the end, regretfully, we passed.
And after a few months of re-negotiating the deal, TRV ended up joining Flagship and Arch and the rest is history. With the closing of the Series A in the spring ofthose three investors worked closely with the founders, and by recruiting CEO David Schenkein and a great team, helped build one of the best aspirational biotechs of the last decade.
In fact, as I understand it, none of initial targets spelled out in the plan played through as tractable cancer programs for the company. But the team and the scientific capabilities of the company were built to go beyond those programs — so when the IDH mutation story emerged inDavid and the Agios team were quick to pounce on it leading to this great Nature paper from their team late that yearwhich became the big value driver for the company and led to their watershed Celgene collaboration.
Looking forward to more great things from Agios over the next decade. But maybe in this case — where that truly special blend of great, inspiring people and cutting edge high impact science came together — we should have thrown caution to the wind and jumped in.
Easy to say in hindsight. The field of chimeric antigen receptor T-cell CART therapy really began to take off after reports of a few compelling patient responses in Check out our interactive graphic of fish from the Gulf of Mexico and their sushi counterparts.
You can also see a video of chef Brandon Fisch preparing a fish ike jime style. Last year, PJ Stoops. Every angler has a story about the one that got awayMADISON - Damon Chandler's story - and potential state record - slipped away in the final minutes of a saga that stretched over several days last week.
After quite a fight, the retired U.S. Navy Hospital Corpsman landed what he thought was a monster yellow bullhead while fishing July 14 just above .
The Fish That Got Away About a month ago while watching the Osprey, a Green Heron landed on the dock below their nest platform with a fish he had just caught.
He immediately decided to swallow it. You searched for: fish got away! Etsy is the home to thousands of handmade, vintage, and one-of-a-kind products and gifts related to your search. No matter what you’re looking for or where you are in the world, our global marketplace of sellers can help you find unique and affordable options.
Let’s get started! The Little Fish That Got Away has 91 ratings and 15 reviews. THE LITTLE FISH THAT GOT AWAYA little boy goes fishing every day, but he never catches any /5. Two Really Big Fish That Got Away Posted March 23rd, in Biotech investment themes, Exits IPOs M&As, VC-backed Biotech Returns Like all avid fly fishermen, I can recount many stories about the big ones that got away.